BALAXI vs CORONA: Stock Comparison
BALAXI PHARMA is the larger company by market capitalisation. BALAXI PHARMA shows a lower P/E, while CORONA REMEDIES shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BALAXI leads 2; CORONA leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BALAXI | CORONA |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | BALAXI | CORONA |
|---|---|---|
| Live Price | ₹21.76 | ₹2,010 |
| Day Change | -1.49% | 0.3% |
| Volume | 19,900 | 17,444 |
| 52-Week High | ₹43.85 | ₹2,292.4 |
| 52-Week Low | ₹15.2 | ₹1,336.6 |
| Distance from 52W High | -50.38% | -12.32% |
Valuation
| Metric | BALAXI | CORONA |
|---|---|---|
| Market Cap | ₹12,013.15 L Cr | ₹12,313 Cr |
| P/E Ratio | 12.63x | 61.87x |
| P/B Ratio | 0x | 16.49x |
| EPS | ₹0.45 | ₹9.83 |
| Book Value | ₹45.12 | ₹122.12 |
| Dividend Yield | 0% | 0.5% |
Growth
| Metric | BALAXI | CORONA |
|---|---|---|
| Revenue Growth (TTM YoY) | -25.76% | 0% |
| EPS Growth (TTM YoY) | -58.44% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | BALAXI | CORONA |
|---|---|---|
| ROE | 0.57% | 24.28% |
| ROCE | 0.85% | 20.94% |
| Net Margin | 0.52% | 13.19% |
| Operating Margin | 3.4% | 15.89% |
| Debt to Equity | 0.22x | 0.19x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | BALAXI | CORONA |
|---|---|---|
| Promoter Holding | 65.99% | 69% |
| FII Holding | 0% | 4.21%▲ 0.58 pp |
| DII Holding | 2.56% | 16.45%▲ 3.55 pp |
| Public Holding | 31.45% | 10.34%▼ 4.14 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALAXI PHARMA and CORONA REMEDIES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.